**MINUTES**

**CPIC CONFERENCE CALL**

DATE: April 5, 2018

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress  | Guideline updates in progress:* *TPMT/NUDT15/*thiopurines*:* drafting guideline
* *CYP2C9/HLA/*phenytoin: Authorship plan approved; first call soon

New guidelines in progress: * *RYR1*/inhaled anesthetics: drafting guideline
* *CYP2B6*/efavirenz: evidence review complete; drafting recommendation and supplemental tables
* *CYP2D6/*atomoxetine: Evidence review complete; drafting recommendation
* *CYP2C19/*PPI: Evidence review underway
* *CYP2C9/*celecoxib: Authorship plan underway
 | Guideline preparation will continue and Kelly will continue to follow-up. |
| Invitation to Collaborate on PGx Insurance Reimbursement | The National Society of Genetic Counselors ([www.nsgc.org](https://na01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nsgc.org&data=01%7C01%7CKelly.Caudle%40stjude.org%7C99cb2eff1ba4420d050d08d594d41d42%7C22340fa892264871b677d3b3e377af72%7C0&sdata=f5YCv4lJv3ZhKZh0H2nL7y6%2BbAS%2FRWU9YsJ86KNS0ng%3D&reserved=0)) PGx Working Group is hoping to collaborate with other PGx professionals on the issue of insurance coverage for PGx testing. The lack of insurance coverage is a tremendous barrier to implementing PGx testing in areas that do not have access to research or academic facilities. This group would like to create a consortium of professionals in the hope that it well give more leverage with the third party payers.  | * If interested in participating, contact Jen Eichmeyer at jennifereichmeye@boisestate.edu.
 |
| Challenges to implementation of RYR1 | Rebecca Pulk discussed the differences in implementing *RYR1* versus other pharmacogenes. Topics discussed included: * Description of the challenge of implementing a somatic marker (similarities/differences to HLAs and other PGx markers)
* Uniqueness of Malignant hyperthermia (potential fatal reaction – medications implicated may be used in an emergent situation – medications involved generally do not go through pharmacy workflow/checkpoints)
* Evolution for implementing MH information at Geisinger
* Draft CPIC Implementation resources for this guideline

Members discussed. Slides attached with minutes. | Full guideline including final implementation resources will be presented on future CPIC call. |
| *CYP2C19* Genotyping Recommendations: AMP PGx Working Group | Vicky Pratt presented results for *CYP2C19* from the PGx working group of the AMP Clinical practice committee whose aim is to recommend variants for inclusion in clinical pharmacogenetic testing panels (PMID 29474986). New working group formed for *CYP2C9*. Slides attached with minutes.  | n/a |